Volume 6 Supplement 2

4th Congress of the Polish Thyroid Association 2013: abstracts of invited lectures and oral presentations

Open Access

Expression mRNA pattern of retinoic acid and retinoid X nuclear receptor subtypes in thyroid carcinomas

  • Julius Brtko1,
  • Dana Macejova1,
  • Stefan Galbavy2,
  • Lucia Bialesová1 and
  • Jan Podoba2
Thyroid Research20136(Suppl 2):A11

DOI: 10.1186/1756-6614-6-S2-A11

Published: 5 April 2013

Retinoid receptors (RARs) upon a proper ligand binding act as all-trans retinoic acid-inducible transcription factors interacting as heterodimers with retinoid X receptors (rexinoid receptors, RXRs).

The objective of this study was to evaluate all retinoid/rexinoid nuclear receptor subtypes (RARalpha, RARbeta, RARgamma, RXRalpha, RXRbeta, RXRgamma) expression pattern in thyroid tumour tissue of patients with different types of thyroid cancer in order to compare it with that of the intact thyroid tissue of the corresponding patient. The expression of the retinoid/rexinoid nuclear receptor subtypes has been analyzed by the semiquantitative RT-PCR technique.

Papillary thyroid carcinoma (PTC) patients expressed RXRgamma when compared to non-neoplastic thyroid tissues of the corresponding patients that were lacking to express RXRgamma or its expression was very low. Moreover, we have found significantly increased expression of RARalpha and RARgamma in overall group of PTC patients. This increase was detected in cases with positive lymph node metastasis (LNM), but not with negative LNM. On the other hand, RARbeta was significantly reduced in the subgroup of classic variant (CV) of papillary carcinoma.

Expression of RXRgamma in the patient with anaplastic carcinoma was found to be lower than that of patients with papillary carcinoma. Follicular adenoma or malignant lymphoma, and also nonmalignant follicular nodules were expressing all RAR and RXR subtypes. On the other hand, hyperplastic nodule was found to express all RAR or RXR subtypes, except RARgamma.

In conclusion, the data on the differences in RAR and RXR subtype mRNA expression patterns in various thyroid carcinomas might thus enhance therapeutical potentialities, and thus they may find exploitation in clinical oncology, predominantly, in the differential diagnostics of human thyroid neoplasms.

Declarations

Acknowledgements

Supported by the grant APVV-0160-11, the VEGA grant 2/0008/11, and the Centre of Excellence CEMAN grant.

Authors’ Affiliations

(1)
Institute of Experimental Endocrinology, Slovak Academy of Sciences
(2)
Saint Elizabeth Institute of Oncology

Copyright

© Brtko et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement